目前药物治疗仍然是帕金森病(PD)临床治疗的主流。近年来,针对多巴胺代谢过程研发新型药物以及PD治疗药物临床随机对照试验研究的开展,为PD患者不同阶段临床治疗药物提供了更多的选择和证据。同时,非运动症状治疗也越来越受到临床重视。合理科学选择药物,既要改善运动症状,也要重视改善非运动症状,以提高PD患者的生活质量,并注重开发具有神经保护作用的药物,将是今后PD药物治疗的方向。
Drug therapy is still the mainstream clinical treatment for Parkinson disease ( PD ). In recent years, new drugs targeting the dopamine(DA) metabolism and large randomized clinical trials and research PD, have provided more choices and evidence for clinical treatment of different stages of PD patients. At the same time,non-motor symptoms treatment is getting more clinical attention. Reasonable choice of drugs, to improve both motor symptoms and non-motor symptoms, to improve the quality of life in patients with PD, and focusing on the development and application of drugs with neuroprotective effects will be the future direction of PD drug treatment.